Morphologic and morphometric evaluation of the effect of ICRF-187 on bleomycin-induced pulmonary toxicity

Toxicology
E H HermanV J Ferrans

Abstract

Morphologic and morphometric studies were made of the protective effects of ICRF-187 against the pulmonary damage induced by bleomycin in male and female C57/BL6 mice. Sixty minutes prior to the subcutaneous administration of 15 mg/kg of bleomycin, animals received either saline or ICRF-187 (300 or 150 mg/kg) intraperitoneally, twice a week for 4 weeks. The lungs of animals treated with bleomycin alone showed inflammation, hyperplasia of type II epithelial cells, squamous cell metaplasia and fibrosis. The extent of fibrosis was quantified by means of a color videometric system and histologic sections of lung stained according to a modified Masson trichrome method. The severity of these alterations, particularly of fibrosis, was reduced in all groups of animals pretreated with ICRF-187. The fibrosis was reduced to a similar extent in female mice treated with the 300 mg/kg and the 150 mg/kg doses of ICRF-187, from 39.3% to 17.6% and 13.3%, respectively. ICRF-187 induced significantly different degrees of reduction in fibrosis in the 2 groups of male mice treated with the 150 mg/kg and the 300 mg/kg doses, from 30% to 19.7% and 12.2%, respectively. In vitro studies indicated that both ICRF-187 and its open-ring hydrolysis product ...Continue Reading

References

Jan 1, 1978·Annals of Internal Medicine·P Y HoloyeC W Bedrossian
Jul 11, 1978·Biochemistry·E A SausvilleS B Horwitz
Jun 1, 1979·Annals of Internal Medicine·J M Bennett, S D Reich
Jan 1, 1990·Chemico-biological Interactions·D H PeteringW E Antholine
Jan 1, 1991·Archives of Toxicology·J HayG Laurent
May 1, 1991·Biochemical Pharmacology·J B LloydC Rice-Evans
Dec 1, 1987·Cancer Treatment Reviews·M E Scheulen
Mar 15, 1988·Toxicology and Applied Pharmacology·D B ChandlerJ D Fulmer
Jun 1, 1988·The American Review of Respiratory Disease·H E WardN Berend
Nov 1, 1971·Thorax·R W FleischmanR D Davis
Feb 16, 1981·Life Sciences·R M BurgerS B Horwitz
May 1, 1983·Proceedings of the National Academy of Sciences of the United States of America·J S Lazo, C J Humphreys
Dec 1, 1983·Cancer Treatment Reviews·F M MuggiaB I Sikic
Jan 1, 1993·Cancer Chemotherapy and Pharmacology·E H Herman, V J Ferrans
Jan 1, 1979·FEBS Letters·L W Oberley, G R Buettner

❮ Previous
Next ❯

Citations

Apr 21, 1998·Critical Reviews in Oncology/hematology·A GiantrisS E Lipshultz
Jul 20, 2002·Journal of Cardiovascular Pharmacology·Helmut SinzingerBernhard A Peskar
Jun 2, 2011·BMC Pulmonary Medicine·Effrosyni D ManaliNikolaos A Maniatis
Feb 5, 2005·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Sarah DansonMalcolm Ranson
Oct 13, 2006·British Journal of Pharmacology·H KaiserováA Bast
Nov 15, 2002·Pediatric Clinics of North America·Debra L Friedman, Anna T Meadows
Mar 20, 2008·International Journal of Cancer. Journal International Du Cancer·George SigounasDimitri G Sigounas
Sep 16, 2000·Chest·A J GhioJ D Carter
Aug 15, 2001·Chest·S Sleijfer
Feb 10, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Cameron K TebbiCindy L Schwartz
Jul 16, 2002·Arteriosclerosis, Thrombosis, and Vascular Biology·Haoyi ZhengStuart D Katz
Nov 13, 2007·Integrative Psychological & Behavioral Science·William R Woodward, Richard S Hetley
Dec 21, 2014·The Journal of Biological Chemistry·Krishna K SinghSubodh Verma
Dec 10, 2015·Cancer Chemotherapy and Pharmacology·S M AttiaS A Bakheet
Oct 31, 2003·Expert Opinion on Drug Safety·Koji Kawai, Hideyuki Akaza

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.